.jpg)
Global Markets Directs, 'Xerosis (Dry Skin) - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Xerosis (Dry Skin), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Xerosis (Dry Skin). Xerosis (Dry Skin) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.
Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of
data for the indicated disease.
Scope
* A snapshot of the global
therapeutic scenario for Xerosis (Dry Skin).
* A review of the Xerosis (Dry Skin)
products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources.
* Coverage of products based on
various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on
the basis of monotherapy and combined therapeutics.
* Coverage of the Xerosis (Dry Skin)
pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline
projects.
* Latest news and deals relating to
the products.
Reasons to buy
* Identify and understand important
and diverse types of therapeutics under development for Xerosis (Dry Skin).
* Identify emerging players with
potentially strong product portfolio and design effective counter-strategies to
gain competitive advantage.
* Plan mergers and acquisitions
effectively by identifying players of the most promising pipeline.
* Devise corrective measures for
pipeline projects by understanding Xerosis (Dry Skin) pipeline depth and focus
of Indication therapeutics.
* Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio
by identifying discontinued projects and understanding the factors that drove
them from pipeline.
To order this report:
Email: support@researchonglobalmarkets.com
US:
+1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
RELATED LINK:
RELATED VIDEO:
No comments:
Post a Comment